Every Form 4 that agilon health, inc. (AGL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGL filings page.
agilon health, inc. (AGL) reported an insider equity transaction by Chief Accounting Officer Timothy Gertsch. On 2026-08-16, 17 shares of common stock were withheld at $96.90 per share to satisfy income tax withholding obligations in connection with the net settlement of restricted stock units; this did not represent an open-market sale. Following this tax-withholding disposition, Gertsch directly held 14,152 shares of common stock, which includes restricted stock units.
agilon health, inc. reports that Chief Legal Officer Denise Zamore had 37 shares of Common Stock withheld on 2026-08-01 to satisfy income tax withholding and remittance obligations related to net settlement of restricted stock units. This is characterized as a tax-withholding disposition and not a sale. Following this transaction, she directly holds 66,075 shares of Common Stock, including restricted stock units.
agilon health, inc. Chief Financial Officer Jeffrey A. Schwaneke reported a routine tax-related share disposition. On the reported date, 2,311 shares of Common Stock were withheld by the company to satisfy income tax withholding and remittance obligations tied to the net settlement of restricted stock units, and this was not an open-market sale. After this withholding, Schwaneke directly holds 138,031 shares of Common Stock, which the disclosure notes includes restricted stock units.
agilon health, inc. Chief Legal Officer Denise Zamore reported a small tax-related share disposition. On the reported date, 485 shares of common stock were withheld by the company to cover income tax obligations from the net settlement of restricted stock units, and this did not involve an open-market sale. After this withholding, she held 66,112 shares directly, including restricted stock units.
Wulf John William reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director John William Wulf received an equity award of 2,133 shares in the form of restricted stock units as compensation. These units vest in full on June 2, 2027, subject to his continued service as a director. After this grant, he beneficially owns 16,765 shares, including restricted stock units, reflecting a 1-for-25 reverse stock split of the company’s common stock that became effective on March 30, 2026.
WILLIAMS RONALD A reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Ronald A. Williams received a grant of 2,133 restricted stock units of common stock, with no cash price per share reported. These units vest in full on June 2, 2027, subject to his continued service as a director.
After this award, Williams beneficially owns 149,141 shares of agilon health common stock, including restricted stock units. The holdings figure reflects a 1-for-25 reverse stock split of the company’s issued and outstanding common stock that became effective on March 30, 2026.
McLoughlin Karen reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Karen McLoughlin reported receiving an equity award of 2,133 shares of common stock in the form of restricted stock units. These units vest in full on June 2, 2027, if she continues serving as a director through that date.
After giving effect to a 1-for-25 reverse stock split effective March 30, 2026, her beneficial ownership, including restricted stock units, totals 8,207 shares of common stock.
agilon health, inc. director Diana McKenzie received an equity grant in the form of restricted stock units. She acquired 2,133 shares of Common Stock at no cash cost as a grant or award, increasing her direct beneficial ownership to a total of 7,633 shares, including restricted stock units. The RSUs vest in full on June 2, 2027, as long as she continues to serve as a director. The ownership figure reflects the company’s 1-for-25 reverse stock split of its common stock that became effective on March 30, 2026.
Mansukani Sharad reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Sharad Mansukani received a grant of 2,133 shares of Common Stock in the form of restricted stock units. These units vest in full on June 2, 2027, contingent on his continued service as a director.
After this award, he beneficially owns 56,242 shares, which include restricted stock units and reflect the company’s 1-for-25 reverse stock split that became effective on March 30, 2026. This filing reflects routine equity compensation rather than an open‑market trade.
Battaglia Silvana reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Silvana Battaglia received an equity award of 2,133 restricted stock units, granted at no cash cost and reported as Common Stock. These RSUs vest in full on June 2, 2027, if she continues serving as a director. Following this grant, her beneficial ownership is 7,926 shares, which includes restricted stock units and reflects a 1-for-25 reverse stock split that became effective on March 30, 2026.
agilon health, inc. Chief Accounting Officer Timothy Gertsch reported a small, routine tax-related share disposition. On this Form 4, 8 shares of Common Stock were withheld by the company at a price of $86.39 per share to cover income tax obligations on vested restricted stock units. Following this withholding, he holds 14,169 shares directly, which still include restricted stock units. The filing clarifies this was not an open-market sale.
O'Rourke Timothy Patrick reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. CEO and President Timothy Patrick O'Rourke reported stock-based compensation awards rather than open-market trades. He received 200,000 shares of Common Stock as a grant on May 7, 2026, increasing his directly held Common Stock to 320,000 shares.
On the same date, he also received a separate 120,000-share award, bringing that holding to 120,000 shares. Footnotes explain that a portion consists of restricted stock units vesting in three equal installments starting on the anniversary of May 7, 2026, and performance stock units that may vest over a three-year period if 30‑trading‑day weighted average prices reach $50, $100 and $150, subject to continued employment.
agilon health, inc. Chief Legal Officer Denise Zamore reported routine share dispositions related to taxes, not open-market sales. On two dates, a total of 240 shares of common stock were withheld by the company to cover income tax obligations from restricted stock unit net settlements.
After these tax-withholding transactions, Zamore directly holds 66,597 shares of agilon health common stock. The footnotes clarify that these entries reflect shares withheld by the issuer to satisfy tax and remittance obligations and “do not represent a sale.”
agilon health, inc. Chief Technology Officer Venkatachaliah Girish reported two small tax-related share dispositions through share withholding, not open-market sales. On April 15, 330 shares of Common Stock were withheld at $26.88 per share, and on April 14, 96 shares were withheld at $22.68 per share.
According to the footnotes, these shares were withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and do not represent sales. After these transactions, Girish directly holds 38,236 shares of Common Stock, and this amount includes restricted stock units.
agilon health, inc. Chief Accounting Officer Timothy Gertsch reported two Form 4 transactions in Common Stock. On April 15, 2026, 122 shares were withheld at $26.88 per share, and on April 14, 2026, 25 shares were withheld at $22.68 per share to satisfy tax obligations from restricted stock unit settlements. These transactions did not involve open-market sales, and Gertsch held 14,177 shares of Common Stock directly after the most recent transaction.
agilon health, inc. Chief Markets Officer Benjamin Shaker reported two small share dispositions that were solely for tax withholding. On April 15, 2026, 571 shares of Common Stock were withheld at $26.88 per share, leaving 122,850 shares held directly. On April 14, 2026, 104 shares were withheld at $22.68 per share, after which he held 123,421 shares. A footnote explains these were shares withheld by the issuer to satisfy income tax obligations in connection with net settlement of restricted stock units and do not represent open-market sales.
agilon health, inc. reported that its Chief Financial Officer, Jeffrey A. Schwaneke, received a grant of 75,000 shares of Common Stock in the form of restricted stock units on April 1, 2026. These restricted stock units vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
On the same date, 1,662 shares of Common Stock were withheld by the company to cover income tax obligations related to the net settlement of restricted stock units, and this did not represent an open-market sale. After these transactions, Schwaneke directly beneficially owned 140,342 shares, which include restricted stock units, and indirectly beneficially owned 892 shares held by a trust. The reported beneficial ownership amounts reflect a 1-for-25 reverse stock split of agilon health’s common stock that became effective on March 30, 2026.
agilon health, inc. reported that Chief Markets Officer Benjamin Shaker received a grant of 70,000 shares of Common Stock in the form of restricted stock units at $0.00 per share. On the same date, 1,664 shares were withheld at $9.75 per share to cover income tax obligations, and this did not represent an open-market sale.
After these transactions, Shaker beneficially owned 123,525 shares of Common Stock, which includes restricted stock units and reflects a 1-for-25 reverse stock split effective March 30, 2026. The restricted stock units vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
agilon health, inc. Chief Accounting Officer Timothy Gertsch reported equity compensation and related tax withholding in Common Stock. He received 10,000 restricted stock units that vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
On the same date, 266 shares of Common Stock were withheld by the company to cover income tax obligations tied to the RSU net settlement; this was a tax-withholding disposition and not an open-market sale. Following these transactions, Gertsch beneficially owned 14,324 shares, a figure that reflects the issuer’s 1-for-25 reverse stock split effective March 30, 2026 and includes RSUs.
agilon health, inc. Chief Technology Officer Venkatachaliah Girish reported routine equity compensation and related tax withholding in company stock. On April 1, 2026, he received a grant of 28,000 shares of Common Stock, described as restricted stock units that vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment. On the same date, 480 shares at $9.75 per share were withheld by the issuer solely to satisfy income tax obligations in connection with the net settlement of restricted stock units and do not represent a sale. Following these transactions, his beneficial ownership increased to 38,662 shares, which the disclosure notes reflects a 1-for-25 reverse stock split of the company’s common stock effective March 30, 2026.
agilon health, inc. Chief Legal Officer Denise Zamore reported routine equity compensation and related tax withholding. She received a grant of 50,000 shares of Common Stock on a grant/award basis, increasing her direct beneficial ownership to 66,837 shares, which includes restricted stock units.
On the same date, 1,024 shares of Common Stock were withheld by the company at $9.75 per share to cover income tax obligations from the net settlement of restricted stock units, and this did not represent an open-market sale. The filing notes a 1-for-25 reverse stock split of agilon health’s common stock effective March 30, 2026, and states that the reported holdings reflect this adjustment. The restricted stock units vest in three equal installments on each anniversary of April 1, 2026, subject to continued employment.
agilon health, inc. Chief Legal Officer Denise Zamore reported equity compensation activity tied to performance-based restricted stock units (PSUs). An award granted on April 14, 2023 fully vested on March 9, 2026 after agilon health achieved 42% of predetermined Revenue and Adjusted EBITDA goals over the three-year period from January 1, 2023 through December 31, 2025.
Each vested PSU settled into one share of common stock, resulting in 5,535 shares reported as acquired. In connection with this net settlement, 2,056 shares of common stock were withheld by the company at $0.5999 per share to satisfy income tax withholding and remittance obligations, which the disclosure notes does not represent a sale. Following these transactions, Zamore directly holds 446,604 shares of common stock, a figure that includes restricted stock units.
agilon health Chief Technology Officer Venkatachaliah Girish reported equity transactions tied to a performance-based restricted stock unit award. On March 9, 2026, he acquired 18,448 shares of Common Stock, reflecting the settlement of vested PSUs granted in April 2023 based on three-year revenue and Adjusted EBITDA goals with 42% attainment.
On the same date, 6,477 shares were withheld by agilon health to cover income tax obligations related to the net settlement of these PSUs, and this withholding is explicitly stated not to represent a sale. After these transactions, Girish directly holds 278,607 shares of Common Stock, including restricted stock units.
agilon health, inc. Chief Markets Officer Benjamin Shaker reported equity-related transactions tied to a performance stock award and a small net share increase. On March 9, 2026, he acquired 18,448 shares of common stock, recorded as an open-market purchase.
On the same date, 6,348 shares were withheld by the company to cover income tax obligations from the vesting and settlement of performance-based restricted stock units (PSUs), and this did not represent a sale. The PSUs, granted on April 14, 2023, vested based on revenue and adjusted EBITDA goals with total attainment of 42%. Following these transactions, Shaker directly holds 1,379,774 shares of common stock, and this figure includes restricted stock units.
agilon health, inc. Chief Markets Officer Benjamin Shaker reported an open-market purchase of 500,000 shares of common stock at a weighted average price of $0.6021 per share. After this transaction, he directly owns 1,367,674 shares, a figure that includes restricted stock units.
Agilon Health director John William Wulf increased his stake in the company. On 11/12/2025, he purchased 81,000 shares of agilon health, inc. common stock in open-market transactions at a weighted average price of $0.6289 per share, with individual trades ranging from $0.6251 to $0.6321.
Following this purchase, he directly beneficially owns 365,857 shares of common stock, which include restricted stock units.
agilon health, inc. reported an insider equity award to its Chief Financial Officer, Jeffrey A. Schwaneke. On January 10, 2026, he received 600,000 shares of common stock in the form of restricted stock units at a stated price of $0 per share. These restricted stock units vest in three equal installments on each anniversary of January 10, 2026, providing a three-year vesting schedule. Following this grant, Schwaneke beneficially owns 1,675,122 shares of agilon health common stock, which includes restricted stock units, all held directly.